Medication Summary
The goals of pharmacotherapy are to reduce morbidity and to prevent complications. Agents used for cholecystitis include antiemetics, analgesics, and antibiotics.
Antiemetics
Class Summary
Patients with cholecystitis frequently experience associated nausea and vomiting. Antiemetics can help make the patient more comfortable and can prevent fluid and electrolyte abnormalities.
Promethazine (Phenergan, Promethegan, Phenadoz)
Promethazine is used for symptomatic treatment of nausea in vestibular dysfunction. It is an antidopaminergic agent effective in treating emesis. It blocks postsynaptic mesolimbic dopaminergic receptors in the brain and reduces stimuli to the brainstem reticular system.
Prochlorperazine (Compazine)
Prochlorperazine may relieve nausea and vomiting by blocking postsynaptic mesolimbic dopamine receptors through anticholinergic effects and depressing the reticular activating system. In addition to antiemetic effects, it has the advantage of augmenting hypoxic ventilatory response, acting as a respiratory stimulant at high altitude.
Analgesics
Class Summary
Pain is a prominent feature of cholecystitis. The classic teaching is that morphine is not the agent of choice because of the possibility of increasing tone at the sphincter of Oddi. Meperidine has been shown to provide adequate analgesia without affecting the sphincter of Oddi and, therefore, is the drug of choice.
Meperidine (Demerol)
Meperidine is the drug of choice for pain control. It is an analgesic with multiple actions similar to those of morphine. It may produce less constipation, smooth muscle spasm, and depression of cough reflex than similar analgesic doses of morphine.
Hydrocodone and acetaminophen (Vicodin, Lortab 5/500, Lorcet-HD)
This drug combination is indicated for moderate to severe pain. Each tab/cap contains 5 mg hydrocodone and 500 mg acetaminophen.
Oxycodone and acetaminophen (Percocet, Tylox, Roxicet)
This drug combination is indicated for relief of moderate to severe pain. Each tab/cap contains 5 mg oxycodone and 325 mg acetaminophen.
Antibiotics
Class Summary
Treatment of cholecystitis with antibiotics should provide coverage against the most common organisms, including Escherichia coli,Bacteroides fragilis, and Klebsiella,Pseudomonas, and Enterococcus species. Current Sanford guide recommendations for the treatment of cholecystitis include ampicillin/sulbactam or piperacillin/tazobactam for non–life-threatening cases of cholecystitis. In life-threatening cases, Sanford recommends imipenem/cilastatin or meropenem. Alternatives include metronidazole plus a third-generation cephalosporin, ciprofloxacin, or aztreonam.
Ciprofloxacin (Cipro)
Ciprofloxacin is a fluoroquinolone that inhibits bacterial DNA synthesis and, consequently, growth, by inhibiting DNA gyrase and topoisomerases, which are required for replication, transcription, and translation of genetic material. Quinolones have broad activity against gram-positive and gram-negative aerobic organisms but no activity against anaerobes. Continue treatment for at least 2 days (7-14 days is typical) after signs and symptoms have disappeared.
Meropenem (Merrem)
Meropenem is a bactericidal broad-spectrum carbapenem antibiotic that inhibits cell wall synthesis. It is effective against most gram-positive and gram-negative bacteria. It has slightly increased activity against gram-negatives and slightly decreased activity against staphylococci and streptococci compared to imipenem.
Imipenem and cilastatin (Primaxin)
This combination is used to treat multiple-organism infections in which other agents do not have wide spectrum coverage or are contraindicated because of potential for toxicity.
Piperacillin and tazobactam (Zosyn)
This combination is an antipseudomonal penicillin plus a beta-lactamase inhibitor. It inhibits biosynthesis of cell wall mucopeptide and is effective during the stage of active multiplication.
Ampicillin and sulbactam (Unasyn)
This drug combination is a beta-lactamase inhibitor with ampicillin. It covers epidermal and enteric flora and anaerobes. It is not ideal for nosocomial pathogens.
Metronidazole (Flagyl)
Metronidazole is an imidazole ring-based antibiotic that is active against various anaerobic bacteria and protozoa. It is used in combination with other antimicrobial agents (except Clostridium difficile enterocolitis).
Levofloxacin (Levaquin)
Levofloxacin is a fluoroquinolone that is used for pseudomonal infections and infections due to multidrug-resistant gram-negative organisms. Prophylactic antibiotic coverage with levofloxacin (Levaquin, 500 mg PO qd) and metronidazole (500 mg PO bid) provides coverage against the most common organisms in cases of uncomplicated cholecystitis.
Aztreonam (Azactam)
Aztreonam is a monobactam, not a beta-lactam, antibiotic that inhibits cell wall synthesis during bacterial growth. It is active against gram-negative bacilli but has very limited gram-positive activity and is not useful for anaerobes. It lacks cross-sensitivity with beta-lactam antibiotics. Aztreonam may be used in patients allergic to penicillins or cephalosporins and is an alternative to life-threatening cases of cholecystitis.
Ceftriaxone (Rocephin)
Ceftriaxone is a third-generation cephalosporin with broad-spectrum, gram-negative activity; it has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. Its bactericidal activity results from inhibiting cell wall synthesis by binding to one or more penicillin-binding proteins. It exerts an antimicrobial effect by interfering with the synthesis of peptidoglycan, a major structural component of bacterial cell walls. Bacteria eventually lyse as a result of the ongoing activity of cell wall autolytic enzymes, while cell wall assembly is arrested.
Cefotaxime (Claforan)
Cefotaxime is a third-generation cephalosporin with a broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms.
Ceftazidime (Fortaz)
Ceftazidime is a third-generation cephalosporin with broad-spectrum, gram-negative activity, including against pseudomonas; it has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms. It arrests bacterial growth by binding to one or more penicillin-binding proteins, which, in turn, inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall synthesis, thus inhibiting cell wall biosynthesis.
Huffman JL, Schenker S. Acute acalculous cholecystitis - a review. Clin Gastroenterol Hepatol. Sep 9 2009;[Medline].
Donovan JM. Physical and metabolic factors in gallstone pathogenesis. Gastroenterol Clin North Am. Mar 1999;28(1):75-97. [Medline].
Sitzmann JV, Pitt HA, Steinborn PA, et al. Cholecystokinin prevents parenteral nutrition induced biliary sludge in humans. Surg Gynecol Obstet. Jan 1990;170(1):25-31. [Medline].
Cullen JJ, Maes EB, Aggrawal S, et al. Effect of endotoxin on opossum gallbladder motility: a model of acalculous cholecystitis. Ann Surg. Aug 2000;232(2):202-7. [Medline].
Forbes LE, Bajaj M, McGinn T, et al. Perihepatic abscess formation in diabetes: a complication of silent gallstones. Am J Gastroenterol. Apr 1996;91(4):786-8. [Medline].
Huang J, Chang CH, Wang JL, Kuo HK, Lin JW, Shau WY, et al. Nationwide epidemiological study of severe gallstone disease in Taiwan. BMC Gastroenterol. Aug 22 2009;9:63. [Medline].
Lee SW, Yang SS, Chang CS, Yeh HJ. Impact of the Tokyo guidelines on the management of patients with acute calculous cholecystitis. J Gastroenterol Hepatol. Aug 3 2009;[Medline].
McEvoy CF, Suchy FJ. Biliary tract disease in children. Pediatr Clin North Am. Feb 1996;43(1):75-98. [Medline].
Gruber PJ, Silverman RA, Gottesfeld S, et al. Presence of fever and leukocytosis in acute cholecystitis. Ann Emerg Med. Sep 1996;28(3):273-7. [Medline].
Liolios A, Oropello JM, Benjamin E. Gastrointestinal complications in the intensive care unit. Clin Chest Med. Jun 1999;20(2):329-45, viii. [Medline].
Chiu HH, Chen CM, Mo LR. Emphysematous cholecystitis. Am J Surg. Sep 2004;188(3):325-6. [Medline].
Moscati RM. Cholelithiasis, cholecystitis, and pancreatitis. Emerg Med Clin North Am. Nov 1996;14(4):719-37. [Medline].
Yates MR 3rd, Baron TH. Biliary tract disease in pregnancy. Clin Liver Dis. 1999;3:131-147.
Singer AJ, McCracken G, Henry MC, et al. Correlation among clinical, laboratory, and hepatobiliary scanning findings in patients with suspected acute cholecystitis. Ann Emerg Med. Sep 1996;28(3):267-72. [Medline].
Katz DS, Rosen MP, Blake MA, et al; and Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® right upper quadrant pain. [online publication]. Reston (VA): American College of Radiology (ACR); 2010:[Full Text].
Towfigh S, McFadden DW, Cortina GR, et al. Porcelain gallbladder is not associated with gallbladder carcinoma. Am Surg. Jan 2001;67(1):7-10. [Medline].
Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery. Jun 2001;129(6):699-703. [Medline].
Bingener J, Schwesinger WH, Chopra S, et al. Does the correlation of acute cholecystitis on ultrasound and at surgery reflect a mirror image?. Am J Surg. Dec 2004;188(6):703-7.
Jang T, Aubin C, Naunheim R. Minimum training for right upper quadrant ultrasonography. Am J Emerg Med. Oct 2004;22(6):439-43. [Medline].
Roe J. Evidence-based emergency medicine. Clinical assessment of acute cholecystitis in adults. Ann Emerg Med. Jul 2006;48(1):101-3. [Medline].
Rosen CL, Brown DF, Chang Y, et al. Ultrasonography by emergency physicians in patients with suspected cholecystitis. Am J Emerg Med. Jan 2001;19(1):32-6. [Medline].
Rubens DJ. Hepatobiliary imaging and its pitfalls. Radiol Clin North Am. Mar 2004;42(2):257-78. [Medline].
Shah K, Wolfe RE. Hepatobiliary ultrasound. Emerg Med Clin North Am. Aug 2004;22(3):661-73, viii. [Medline].
Kim YK, Kwak HS, Kim CS, Han YM, Jeong TO, Kim IH, et al. CT findings of mild forms or early manifestations of acute cholecystitis. Clin Imaging. Jul-Aug 2009;33(4):274-80. [Medline].
Sahai AV, Mauldin PD, Marsi V, et al. Bile duct stones and laparoscopic cholecystectomy: a decision analysis to assess the roles of intraoperative cholangiography, EUS, and ERCP. Gastrointest Endosc. Mar 1999;49(3 Pt 1):334-43. [Medline].
Greenwald JA, McMullen HF, Coppa GF, et al. Standardization of surgeon-controlled variables: impact on outcome in patients with acute cholecystitis. Ann Surg. Mar 2000;231(3):339-44. [Medline].
Siddiqui T, MacDonald A, Chong PS, et al. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a meta-analysis of randomized clinical trials. Am J Surg. Jan 2008;195(1):40-7. [Medline].
Cox MR, Wilson TG, Luck AJ, et al. Laparoscopic cholecystectomy for acute inflammation of the gallbladder. Ann Surg. Nov 1993;218(5):630-4. [Medline].
Lo CM, Liu CL, Fan ST, et al. Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Ann Surg. Apr 1998;227(4):461-7. [Medline].
[Guideline] Overby DW, Apelgren KN, Richardson W, Fanelli R. SAGES guidelines for the clinical application of laparoscopic biliary tract surgery. Surg Endosc. Oct 2010;24(10):2368-86. [Medline].
[Best Evidence] Wilson E, Gurusamy K, Gluud C, Davidson BR. Cost-utility and value-of-information analysis of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Br J Surg. Feb 2010;97(2):210-9. [Medline].
Binenbaum SJ, Teixeira JA, Forrester GJ, Harvey EJ, Afthinos J, Kim GJ, et al. Single-incision laparoscopic cholecystectomy using a flexible endoscope. Arch Surg. Aug 2009;144(8):734-8. [Medline].
Wu CH, Chen CC, Wang CJ, et al. Discrimination of gangrenous from uncomplicated acute cholecystitis: Accuracy of CT findings. Abdom Imaging. Apr 2011;36(2):174-8. [Medline].
Silberfein EJ, Zhou W, Kougias P, et al. Percutaneous cholecystostomy for acute cholecystitis in high-risk patients: experience of a surgeon-initiated interventional program. Am J Surg. Nov 2007;194(5):672-7. [Medline].
Mutignani M, Iacopini F, Perri V, et al. Endoscopic gallbladder drainage for acute cholecystitis: technical and clinical results. Endoscopy. Jun 2009;41(6):539-46. [Medline].
Lee SS, Park do H, Hwang CY, et al. EUS-guided transmural cholecystostomy as rescue management for acute cholecystitis in elderly or high-risk patients: a prospective feasibility study. Gastrointest Endosc. Nov 2007;66(5):1008-12. [Medline].

